RCAN2 functions as an inhibitor of calcineurin-dependent signaling by binding to the catalytic domain of calcineurin A 1. While the UniProt annotation suggests a role in CNS development, current evidence primarily demonstrates its involvement in metabolic and oncologic processes. Metabolically, RCAN2 promotes food intake and weight gain through a leptin-independent hypothalamic mechanism 2. Rcan2 expression is enriched in ventromedial, dorsomedial, and paraventricular hypothalamic nuclei, and its genetic inactivation reduces food intake and ameliorates age- and diet-induced obesity in mice 2. In humans, serum RCAN2 concentrations correlate positively with BMI and overweight/obesity risk, with elevated levels also associated with metabolic abnormalities including dyslipidemia 3. RCAN2 similarly associates with non-alcoholic fatty liver disease (NAFLD) risk in humans and is upregulated in hepatic steatosis models 4. Oncologically, RCAN2 suppression enhances cancer stem cell properties in colorectal cancer by allowing calcineurin-dependent NFATC1 activation 5. In gliomas, RCAN2 dysregulation via circRNA-mediated mechanisms influences tumor growth through apoptotic pathways 6. Additionally, RCAN2 participates in p53 mutant pro-tumorigenic networks in pancreatic cancer 7. These findings position RCAN2 as a metabolic and oncologic regulator with potential diagnostic and therapeutic significance across multiple disease states.